Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003556priorityCriticalpatent/ECSP003556A/en
Publication of ECSP003556ApublicationCriticalpatent/ECSP003556A/en
Se describieron los compuestos de indazol que modulan y/o inhiben la actividad de ciertas quinasas de proteina. Estos compuestos y composiciones farmacéuticas que los contienen son capaces de mediar la transducción señalada de quinasa tirosina y asi modulan y/o inhiben la proliferación de células superfluas. El invento es dirigido también para el uso terapéutico y farmaco de las composiciones farmacéuticas que contienen tales compuestos y para los métodos de tratar el cáncer y otras enfermedades asociadas a angiogpénesis superfluo y/o la proliferación celular, como retinopatia diabética glucoma noevascular, artritis reumatoide y soriasis por administra cabntidades efectivas de tales compuestos.Indazole compounds that modulate and / or inhibit the activity of certain protein kinases were described. These compounds and pharmaceutical compositions containing them are capable of mediating the indicated transduction of tyrosine kinase and thus modulate and / or inhibit the proliferation of superfluous cells. The invention is also directed to the therapeutic and pharmaceutical use of pharmaceutical compositions containing such compounds and to methods of treating cancer and other diseases associated with superfluous angiogenesis and / or cell proliferation, such as diabetic retinopathy, noevascular glucoma, rheumatoid arthritis, and psoriasis by administering effective amounts of such compounds.
ECSP0035562000-06-302000-06-30
INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF PROTEIN KINASE AND METHODS FOR USE
ECSP003556A
(en)